All In Biotech

NDA 209483 · Primus Pharms

Impoyz

Clobetasol Propionate · Topical

Last checked: Nov 20, 2026Latest source record: Nov 28, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Nov 28, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

119

23 Phase 3, 10 recruiting

FAERS reports

10,709

4,983 serious, 441 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 13, 2025.

INDICATIONS AND USAGE Clobetasol Propionate Cream is a corticosteroid indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age and older. (1)

Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid responsive dermatoses is unknown. The contribution to efficacy by individual components of the vehicle has not been established. 16.1 How Supplied Clobetasol Propionate Cream, 0.025% is a white to off-white cream, supplied as follows: 100g aluminum tube NDC 74157-710-10

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 28, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • IMPOYZ · CLOBETASOL PROPIONATE 0.025% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clobetasol Propionate" as an intervention, any sponsor and status, largest first.

All 119 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,119
  • pruritus990
  • off label use687
  • rash686
  • product use in unapproved indication559
  • psoriasis555
  • fatigue536
  • headache503
  • diarrhoea450
  • nausea445
  • dry skin426
  • arthralgia422

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200520
200658
200792
200895
2009125
2010135
2011215
2012318
2013162
2014185
2015346
2016403
2017536
2018464
2019477
2020560
2021608
2022926
20231,254
20241,175
20251,342
20261,196

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 257 on PubMed

Sponsor: Primus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.